{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:27:18Z","timestamp":1782602838897,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T00:00:00Z","timestamp":1440460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10067-015-3059-y","type":"journal-article","created":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T02:50:04Z","timestamp":1440384604000},"page":"2089-2095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review"],"prefix":"10.1007","volume":"34","author":[{"given":"Erin","family":"Vermaak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Tansley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,25]]},"reference":[{"key":"3059_CR1","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 339:b2700","DOI":"10.1136\/bmj.b2700"},{"key":"3059_CR2","unstructured":"Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org"},{"key":"3059_CR3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"3059_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403\u2013407","journal-title":"N Engl J Med"},{"key":"3059_CR5","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487\u20131498","journal-title":"N Engl J Med"},{"key":"3059_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"3059_CR7","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","volume":"50","author":"LG Rider","year":"2004","unstructured":"Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM et al (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50:2281\u20132290","journal-title":"Arthritis Rheum"},{"key":"3059_CR8","first-page":"CD003643","volume":"8","author":"PA Gordon","year":"2012","unstructured":"Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Sys Rev 8:CD003643","journal-title":"Cochrane Database Sys Rev."},{"key":"3059_CR9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324","journal-title":"Arthritis Rheum"},{"key":"3059_CR10","doi-asserted-by":"crossref","unstructured":"Ibrahim F, Choy E, Gordon P, Dore CJ, Hakim A, Kitas G, et al. (2014) Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology","DOI":"10.1093\/rheumatology\/keu442"},{"key":"3059_CR11","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993\u20132000","journal-title":"N Engl J Med"},{"key":"3059_CR12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","volume":"41","author":"L Villalba","year":"1998","unstructured":"Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL et al (1998) Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:392\u2013399","journal-title":"Arthritis Rheum"},{"key":"3059_CR13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","volume":"20","author":"J Vlekkert van de","year":"2010","unstructured":"van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL et al (2010) Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 20:382\u2013389","journal-title":"Neuromuscul Disord"},{"key":"3059_CR14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","volume":"22","author":"N Miyasaka","year":"2012","unstructured":"Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y (2012) Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 22:382\u2013393","journal-title":"Mod Rheumatol"},{"key":"3059_CR15","doi-asserted-by":"crossref","unstructured":"(2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 70:427-36.","DOI":"10.1002\/ana.22477"},{"key":"3059_CR16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"TW Bunch","year":"1980","unstructured":"Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Int Med 92:365\u2013369","journal-title":"Ann Int Med"},{"key":"3059_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/030097400750001897","volume":"29","author":"J Vencovsky","year":"2000","unstructured":"Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkov J, Bartunkov J et al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95\u2013102","journal-title":"Scand J Rheumatol"},{"key":"3059_CR18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/ard.41.6.557","volume":"41","author":"P Hollingworth","year":"1982","unstructured":"Hollingworth P, de Vere TA, Ansell BM, Platts-Mills T, Gumpel JM, Mertin J et al (1982) Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. Ann Rheum Dis 41:557\u2013562","journal-title":"Ann Rheum Dis"},{"key":"3059_CR19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","volume":"94","author":"K Amemiya","year":"2000","unstructured":"Amemiya K, Semino-Mora C, Granger RP, Dalakas MC (2000) Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94:99\u2013104","journal-title":"Clin Immunol"},{"key":"3059_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24:45\u201348","journal-title":"Arthritis Rheum"},{"key":"3059_CR21","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","volume":"326","author":"FW Miller","year":"1992","unstructured":"Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R et al (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326:1380\u20131384","journal-title":"N Engl J Med"},{"key":"3059_CR22","first-page":"494","volume":"58","author":"FR Convery","year":"1977","unstructured":"Convery FR, Minteer MA, Amiel D, Connett KL (1977) Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 58:494\u2013499","journal-title":"Arch Phys Med Rehabil"},{"key":"3059_CR23","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW (1965) Functional Evaluation: The Barthel Index. Maryland State Med J 14:61\u201365","journal-title":"Maryland State Med J"},{"key":"3059_CR24","doi-asserted-by":"crossref","unstructured":"(1996) The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurology. 53:141-7","DOI":"10.1001\/archneur.1996.00550020045014"},{"key":"3059_CR25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile Dermatomyositis and adult polymyositis. Arthritis Rheum 66:740\u2013749","journal-title":"Arthritis Rheum"},{"key":"3059_CR26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE et al (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94:379\u2013387","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"3059_CR27","first-page":"S53","volume":"199","author":"JWY Miller","year":"2002","unstructured":"Miller JWY, Saminaden S, Lecky BRF, Winer JB (2002) Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 199(Suppl 1):S53","journal-title":"J Neurol Sci"},{"issue":"Suppl 2","key":"3059_CR28","first-page":"O19","volume":"11","author":"N Ruperto","year":"2013","unstructured":"Ruperto N, Pistorio A (2013) Knupp Feitosa de Oliveira S, Cuttica R, Ravelli A, Fischbach M, et al. A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisolone plus cyclosporine versus prednisone plus methotrexate. Pediatric. Rheumatology 11(Suppl 2):O19","journal-title":"Rheumatology"},{"issue":"suppl 1","key":"3059_CR29","doi-asserted-by":"crossref","first-page":"i127","DOI":"10.1093\/rheumatology\/keu108.001","volume":"53","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Sharp C, McHugh N, Christopher-Stine L, Chinoy H (2014) Developing Standardized Treatment for Adults with Myositis and Different Phenotypes. Rheumatology 53(suppl 1):i127","journal-title":"Rheumatology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3059-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-3059-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3059-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T19:04:54Z","timestamp":1567105494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-3059-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["3059"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-3059-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,25]]}}}